“Drug Repurposing of Loratadine as a DNMT1 Inhibitor: Comparative Evaluation with Cisplatin in Patient-Derived Oral Squamous Cell Carcinoma Cells” (2024) Precision Medicine Communications, 4(2), pp. 125–137. doi:10.55627/pmc.004.02.1083.